About

➀ Read and Learn

The following course content

Introduction   

Pancreatic cancer presents formidable challenges in treatment, stemming from its affinity to spread, along with the unique biological properties of its tumors. Pancreatic ductal adenocarcinoma (PDAC), originating from pancreatic epithelial cells, stands as the predominant type of pancreatic cancer [1].  

Pancreatic ductal adenocarcinoma (PDAC) ranks as the fourth leading cause of cancer-related fatalities across the globe, characterized by a low five-year overall survival rate of under 8% [1]. This increased mortality of pancreatic cancer, with its distinctive tumor microenvironment (TME), is characterized by a significant desmoplastic stromal microenvironment, a dense extracellular matrix, a range of activated cell types, hypoxic conditions, and an acidic extracellular pH make pancreatic cancer one of the most complex [2]. This active desmoplastic stroma poses challenges to effective treatment [2].  

To combat pancreatic cancer, it is imperative to achieve total elimination of all cancer cells from the body [3]. This involves addressing both the primary tumor in the pancreas and any microscopic cancer cells that may have dispersed elsewhere. The most effective treatment for pancreatic cancer occurs through early detection [41]. 

The higher mortality rate associated with pancreatic cancer is due to two factors: 

1. Early Metastasis: Pancreatic cancer tends to metastasize at an early stage. In 85% of cases, the cancer has already spread beyond the pancreas at diagnosis [4].  
2. Genetic Reprogramming During Migration: As pancreatic cancer cells migrate to other organs including the liver, they undergo genetic changes that strengthen the underlying cell [4].  

Effective pancreatic cancer treatment targets two primary aspects: 

1. Local Disease Management: Focused on the primary, or Stage 1, tumor in the pancreas. 10% of patients diagnosed early with pancreatic cancer achieve a disease-free status following treatment. The average survival time for pancreatic cancer is 3 to 3.5 years for patients diagnosed before the tumor grows or spreads [5]. 
2. Systemic Disease Management: Cells from the pancreatic tumor can detach, enter the bloodstream, and circulate to distant organs, forming new tumors. Cancer cells tend to break away from the primary tumor, influenced by paracrine and autocrine signaling mechanisms [6]. These signals coordinate a multi-step process for the cancer cells, concluding in their establishment and colonization within distant tissues [6]. 

Case Study: Pancreatic Cancer Treatment and Staging 

Patient Profile: 

Name: John Doe 

Age: 58 years 

Medical History: Non-smoking, moderate alcohol use, no significant family history of cancer. 

Presenting Complaint: The patient presents with a 2-month history of upper abdominal pain, unexplained weight loss, and jaundice. 

Initial Assessment and Diagnosis: 

Physical Examination: Noticeable jaundice, and mild abdominal tenderness. 

Blood Tests: Elevated liver enzymes, CA 19-9 tumor marker levels. 

Imaging: Abdominal CT scan reveals a mass in the head of the pancreas, no apparent liver metastases. 

Diagnosis:

Based on clinical presentation and investigations, the patient receives a preliminary diagnosis of pancreatic cancer. 

Staging: 

MRI and endoscopic ultrasound (EUS) to assess local invasion and lymph node involvement. 

PET scan to rule out distant metastasis. 

Findings:

There is no evidence of distant spread with localized lymph node involvement noted. 

Stage Determination:

Stage IIB (T3, N1, M0) – The tumor is advanced but without distant metastasis. 

Treatment Plan: 

Multidisciplinary Team (MDT) Consultation: Involves oncologists, surgeons, radiologists, and gastroenterologists. 

Neoadjuvant Therapy: Given the local advancement, the treatment team opts for neoadjuvant chemotherapy to shrink the tumor and improve surgical outcomes. 

Surgical Intervention: After reassessment, the patient undergoes a Whipple procedure (pancreaticoduodenectomy) to remove the tumor. 

Adjuvant Therapy: Post-surgical chemotherapy combined with radiation therapy, to address any residual microscopic disease. 

Follow-Up and Monitoring:  

Regular follow-up visits, imaging, and CA 19-9 levels monitoring for early detection of recurrence. 

Prognosis and Patient Education: 

With vigilant monitoring, the patient’s prognosis is optimistic, considering the early stage and response to treatment.  

Education: Patient education on post-surgical care, lifestyle modifications, and importance of follow-up assist the patient with coping after the diagnosis. 

Conclusion:  

This case study illustrates the importance of early detection and a comprehensive, multidisciplinary approach in the management of pancreatic cancer, considering current treatment and staging guidelines.  

Statistical Evidence/Epidemiology  

The global incidence of pancreatic cancer shows significant variation across different regions and populations [7]. Pancreatic cancer ranks as the twelfth most common cancer in men, the eleventh in women, and is the seventh leading cause of cancer-related deaths worldwide [8]. The risk of developing pancreatic cancer increases with age with most people who develop pancreatic cancer older than 45 [9]. 90% are older than 55 and 70% are older than 65 [9]. 

According to the International Agency for Research on Cancer’s (IARC) GLOBOCAN data, in 2018, there were 458,918 new cases and 432,242 deaths from pancreatic cancer across the globe, representing 2.5% of all new cancer cases and 4.5% of all cancer deaths [8]. 

There has been an increasing trend in pancreatic cancer incidence observed in recent decades, with projections suggesting a continued rise [10]. This increase factors in modifiable variables including tobacco use, obesity, diabetes, physical inactivity, and high calorie/fat diets in certain regions, alongside advancements in clinical diagnosis and an aging global population [9].  

A 2023 review in the Journal Cell reports that pancreatic cancer has become the third leading cause of cancer-related deaths in the US, surpassing breast cancer in mortality rates [10]. Projections indicate that by 2040, pancreatic cancer will overtake colorectal cancer, becoming the second leading cause of cancer-related deaths in the US [10].  

Pancreatic cancer incidence is three to four times higher in developed countries compared to developing ones. Europe and North America report the highest rates, while the lowest are in Africa and South-Central Asia [7]. In 2019, an estimated 56,770 new cases, and 45,750 deaths occurred [12]. Higher rates appear in Black populations compared to White, although the rate of increase is faster among Whites [13].  

Researchers have discovered that pancreatic cancer rates are rising in both men and women [13]. In women under 55, the increase in rates was 2.4% higher compared to men in the same age group [13]. Similar trends of increased rates occur in older men and women. The rates in young Black women are 2.23% higher than those in young Black men [13].  

In 2021, there was a slight gender difference in the incidence rates of pancreatic cancer, with the condition being more common in men at a rate of 5.5 per 100,000, representing 243,033 cases, compared to women, who had a rate of 4.0 per 100,000, amounting to 215,885 cases. [14].  

Etiology/Pathophysiology 

Extensive research, including various meta-analyses and pooled studies, has identified a spectrum of risk factors associated with pancreatic cancer. These factors fall into two categories: those that are modifiable and those that are non-modifiable.  

Modifiable Risk Factors: 

Smoking: A leading environmental factor for pancreatic cancer, with the risk increasing with the duration and intensity of smoking. Smokers have twice the risk of developing pancreatic cancer compared to non-smokers [15]. Smoking is responsible for up to 25% of pancreatic cancer cases [15]. 

Alcohol: High alcohol consumption (more than three drinks per day) increases the risk of pancreatic cancer, in combination with smoking [16]. 

Obesity: Linked to an increased risk of various cancers, including pancreatic cancer, with studies showing higher incidence and mortality rates among obese individuals [17]. 

Dietary Factors: The consumption of red and processed meats, fried foods, and foods high in cholesterol and nitrosamines elevates the risk of pancreatic cancer [18]. A diet rich in fruits and vegetables may offer protective benefits [19]. 

Occupational Exposures: Patients with occupational and environmental contact with cadmium, arsenic, lead, selenium, nickel, and chromium have a heightened risk of exocrine pancreatic cancer (EPC) [20]. 

Non-modifiable Risk Factors: 

Gender: Pancreatic cancer is more prevalent in men than women [8]. 

Age: Most common among individuals over 50 years of age [9]. 

Ethnicity: Incidence rates vary among different ethnic groups, with African Americans showing higher rates than Caucasians [13]. 

Diabetes Mellitus: Both types I and II diabetes are associated with an increased risk of pancreatic cancer [15]. 

Family History and Genetic Factors: Familial history and genetic mutations account for a significant percentage of pancreatic cancer cases [15]. 

Infections: Certain chronic infections, such as H. pylori, have been associated with an increased risk of pancreatic cancer [22]. 

ABO Blood Group:  Researchers evaluated the data and when compared to type O those individuals with type A blood had a 32% increased risk of developing pancreatic cancer, those with type AB had a 51% higher risk, and those with type B faced a 72% greater risk [23]. 

Genetic Cause: Ten percent of patients have genetic mutations or associations with syndromes such as Lynch syndrome, Peutz-Jeghers syndrome, Von Hippel-Lindau Syndrome, and MEN1 (multiple endocrine neoplasia type 1) [24].  

Pancreatic adenocarcinoma and its variants represent about 90% of all pancreatic cancer types. 60%-70% of pancreatic adenocarcinomas originate in the pancreas’s head, while the body and tail each account for about 15% of cases [29].  

Pancreatic cancer may originate as adenocarcinoma, serous, seromucinous, or mucinous types and its development is a complex process that involves intricate interactions between tumor cells and their surrounding environment, accompanied by a range of molecular changes [21]. These dynamic interactions and modifications play a vital role in both the initiation and advancement of the disease.  

PDAC (Pancreatic Ductal Adenocarcinoma) develops from curable noninvasive precancerous lesions if detected and treated early [25]. The classification of these lesions is based on size and involvement with the pancreatic ductal system. Most PDACs originate from PanIN (pancreatic intraepithelial neoplasia), microscopic neoplasms affecting pancreatic ducts smaller than 5 mm [25]. A smaller proportion (<10%) of PDACs come from IPMNs (intraductal papillary mucinous neoplasms), which are macrocystic lesions involving the ductal system [25].  

The tumor microenvironment (TME) plays a critical role in the development of pancreatic cancer (PC) and the failure of treatments [26]. Pancreatic tumors consist not just of tumor cells but also of various cell types like fibroblasts, immune cells, and endothelial cells [27]. Pancreatic tumor cells can induce epigenetic modifications in cancer-associated fibroblasts (CAFs), such as DNA methylation of the SOCS1 gene, which in turn promotes tumor growth [28].  

Diagnostic and Screening tools 

Ongoing research focuses on developing and utilizing innovative blood tests, diagnostic imaging techniques, and other methods to identify pancreatic cancer in its initial stages before it can spread [30]. This effort includes detecting precancerous stages, such as pancreatic intraepithelial neoplasia (PanIN lesions) [29].  

These screening methods are employed for individuals at elevated risk of developing pancreatic cancer including those with a significant family history or known genetic predispositions to the disease. There are no established screening tests that can detect pancreatic cancer in its initial stages, before the onset of symptoms [30]. 

Medication Management 

Cancer researchers are exploring several types of immunotherapies as potential treatments for pancreatic cancer, including cancer vaccines made from various sources like pancreatic cancer cells, bacteria, or a person’s specific tumor cells, administered during various stages of treatment [31]. Immune checkpoint inhibitors, such as anti-PD-1 antibodies, already approved for other cancers, are under investigation for pancreatic cancer in patients with high microsatellite instability [32]. Targeted therapies approved for pancreatic cancer include erlotinib, olaparib, larotrectinib, and entrectinib, with ongoing research into drugs that block tumor growth in those targeting the KRAS gene and its mutations, and strategies to inhibit autophagy and break down tumor-associated stroma to enhance chemotherapy effectiveness [33].  

Targeted therapies for pancreatic cancer focus on various approaches including Ras-Directed Therapies that alter RAS genes, are pivotal in cell growth signaling, and exist in over 90% of pancreatic cancers [30].  

Pancreatic cancer can evade the immune system through several strategies, such as its immunosuppressive, dense fibrotic tumor microenvironment, and low tumor mutational burden [34]. Immunotherapy holds promise in eradicating cancer cells by reactivating the body’s cancer-fighting immune response with Pembrolizumab (Keytruda), an immune checkpoint inhibitor targeting pancreatic cancer patients with high microsatellite instability (MSI) [34]. 

Common Misconceptions 

There are several misconceptions about pancreatic cancer, some of which include the common idiom that pancreatic cancer is a death sentence. While pancreatic cancer can be aggressive and difficult to treat if diagnosed late, advances in treatment and early detection are improving outcomes for some patients [25].  

There is the misconception that only individuals with a family history get pancreatic cancer. Though a family history of pancreatic cancer can increase risk, most cases occur in people without a known family history [38]. 

Many believe pancreatic cancer is symptomless. In truth, early-stage pancreatic cancer often does not cause symptoms, which makes diagnosis difficult. Symptoms such as jaundice, abdominal pain, pancreatitis, new onset unexplained weight loss, and changes in stool can be indicative of pancreatic cancer [39]. 

You cannot reduce your risk of Pancreatic Cancer: Certain lifestyle factors, including smoking, obesity, and a diet high in processed and red meats, can increase the risk of developing pancreatic cancer. Reducing these risk factors can lower the risk [19]. 

Pancreatic Cancer Only Affects Older Adults: While the risk of pancreatic cancer increases with age, it can affect younger adults as well [9]. 

All Pancreatic Tumors are the Same: There are diverse types of pancreatic cancer, such as adenocarcinoma and neuroendocrine tumors, which behave differently and may require different treatment approaches [21]. 

Upcoming Research 

Genetic and molecular studies in cancer focus on identifying and modifying damaged genes and proteins to control uncontrolled cell growth. Recent progress in tumor genetics has led to the identification of circulating tumor DNA (ctDNA) [36]. There is an increasing amount of evidence that highlights the effectiveness of these sensitive biomarkers in identifying residual disease, diagnosing recurrence, and facilitating the use of targeted and tumor-specific adjuvant treatments [37].  

Through a simple blood draw or urine sample providers can analyze circulating tumor DNA (ctDNA), which is cancer cell-derived DNA found in the bloodstream [35] [36]. The study of ctDNA is gaining traction as a means to monitor tumor response to treatment, detect early signs of disease recurrence, and understand the disease’s resistance to current treatments.  

Researchers have subjected pancreatic tumor samples to various molecular techniques including DNA sequencing and mutational analysis to detect genetic alterations [35]. The insights gained from these studies are crucial for developing new drugs targeting these genetic changes.  

Conclusion

Pancreatic Ductal Adenocarcinoma (PDAC), characterized by early metastasis, aggressive tumor microenvironment, and a propensity for genetic reprogramming during migration, is one of the deadliest cancer types [40]. The case study of John Doe exemplifies the crucial role of early detection and a multidisciplinary treatment approach, emphasizing the importance of both local and systemic disease management to achieve optimal outcomes. 

The identification of both modifiable and non-modifiable risk factors provides avenues for preventive strategies and targeted interventions. In terms of treatment, advancements in immunotherapy, targeted therapies, and genetic research hold promise [36]. However, the challenges posed by the tumor’s microenvironment and genetic complexity continue to hinder effective treatment modalities. The exploration of innovative diagnostic tools like circulating tumor DNA (ctDNA) and molecular techniques in tumor analysis are pivotal in the early detection and personalized treatment of pancreatic cancer [36].  

The fight against pancreatic cancer necessitates a concerted effort in research, early detection, comprehensive treatment strategies, and public education.  

➁ Complete Survey

Give us your thoughts and feedback

➂ Click Complete

To receive your certificate